MedicalResearch.com Interview with:
Renato D. Lopes MD, MHS, PhD
Professor of Medicine, Division of Cardiology
Duke University Medical Center
Duke Clinical Research Institute
Terrace Level, Durham, NC 27705
MedicalResearch.com: What is the background for this study?
1- Digoxin is used in ≈ 30% of patients with atrial fibrillation (AF) worldwide, despite the lack of randomized clinical trials to assess its efficacy and safety in this setting.
2- Current AF guidelines recommend digoxin for rate control in patients with AF with and without heart failure (HF).
3- There are no specific recommendations about serum digoxin concentration monitoring in the atrial fibrillation guidelines.